Home
/
COLLEGIUM PHARMACEUTICAL, INC
/
Financials
/
Quarterly
COLLEGIUM PHARMACEUTICAL, INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that COLLEGIUM PHARMACEUTICAL, INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$209.36M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$188.00M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$177.76M
May 8, 2025
Q3
2025
Sep 30, 2024
$159.30M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$145.28M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$144.92M
May 8, 2025
Q3
2024
Sep 30, 2023
$136.71M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$135.55M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$144.77M
May 9, 2024
Q3
2023
Sep 30, 2022
$127.01M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$123.55M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$83.75M
May 4, 2023
Q3
2022
Sep 30, 2021
$78.84M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$82.94M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$87.72M
May 10, 2022
Q3
2021
Sep 30, 2020
$79.18M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$78.06M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$76.51M
May 6, 2021
Q3
2020
Sep 30, 2019
$72.94M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$75.04M
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$31.51M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$11.98M
Aug 7, 2025
Q3
2025
Jun 30, 2025
$11.98M
Nov 6, 2025
Q1
2025
Mar 31, 2025
$2.42M
May 8, 2025
Q3
2025
Mar 31, 2025
$2.42M
Nov 6, 2025
Q2
2025
Mar 31, 2025
$2.42M
Aug 7, 2025
Q3
2025
Sep 30, 2024
$9.34M
Nov 6, 2025
Q3
2025
Jun 30, 2024
$19.61M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$19.61M
Aug 7, 2025
Q2
2025
Mar 31, 2024
$27.71M
Aug 7, 2025
Q3
2025
Mar 31, 2024
$27.71M
Nov 6, 2025
Q1
2025
Mar 31, 2024
$27.71M
May 8, 2025
Q3
2024
Sep 30, 2023
$20.63M
Nov 7, 2024
Q3
2024
Jun 30, 2023
$13.01M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$13.01M
Aug 8, 2024
Q1
2024
Mar 31, 2023
($17.43M)
May 9, 2024
Q2
2024
Mar 31, 2023
($17.43M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($17.43M)
Nov 7, 2024
Q3
2023
Sep 30, 2022
$457.0K
Nov 7, 2023
Q3
2023
Jun 30, 2022
($5.19M)
Nov 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$62.09M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$35.11M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$21.69M
May 8, 2025
Q3
2025
Sep 30, 2024
$34.84M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$47.47M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$49.47M
May 8, 2025
Q3
2024
Sep 30, 2023
$45.01M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$35.63M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$24.63M
May 9, 2024
Q3
2023
Sep 30, 2022
$20.47M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$11.11M
Aug 3, 2023
Q1
2023
Mar 31, 2022
($10.02M)
May 4, 2023
Q3
2022
Sep 30, 2021
$14.15M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$16.41M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$21.19M
May 10, 2022
Q3
2021
Sep 30, 2020
$19.63M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$16.55M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$5.06M
May 6, 2021
Q3
2020
Sep 30, 2019
($6.38M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($5.01M)
Aug 5, 2020